What adjuvant chemotherapy regimen is recommended for a patient with goblet‑cell adenocarcinoma of the appendix with lymph node metastasis after surgical resection?

Adjuvant Chemotherapy for Goblet Cell Adenocarcinoma with Lymph Node Metastasis

For goblet cell adenocarcinoma of the appendix with lymph node involvement after surgery, use FOLFOX (5-fluorouracil/leucovorin plus oxaliplatin) for 6 months as adjuvant chemotherapy.

Rationale and Evidence Base

While no specific guidelines exist for goblet cell adenocarcinoma (GCA), the treatment approach borrows from colorectal cancer protocols given the adenocarcinoma component of this tumor. The available evidence, though limited to case series, consistently supports oxaliplatin-based regimens.

Primary Recommendation: FOLFOX Regimen

The most appropriate chemotherapy is FOLFOX (5-fluorouracil/leucovorin plus oxaliplatin) for 6 months 1, 2. This recommendation is based on:

• Colon cancer guidelines establish FOLFOX as standard adjuvant therapy for stage III disease (node-positive) 1
• Multiple case reports demonstrate successful outcomes with oxaliplatin-based chemotherapy in GCA with lymph node metastases 3, 4
• One case series showed patients treated with FOLFOX or CapeOX (capecitabine plus oxaliplatin) remained disease-free for 22-36+ months after surgery 4

Alternative Regimen: CapeOX

Capecitabine plus oxaliplatin (CapeOX) is an acceptable alternative, particularly if:

• Patient preference favors oral therapy over infusional treatment
• Venous access is problematic
• The patient has contraindications to infusional 5-FU

This regimen has demonstrated equivalent efficacy in colorectal cancer 1 and has been successfully used in GCA 4.

Treatment Duration and Monitoring

• Duration: 6 months of adjuvant chemotherapy
• Timing: Begin within 6-8 weeks post-surgery once adequate recovery achieved
• Surveillance: Given GCA's unpredictable behavior, lifelong surveillance is warranted even after completing chemotherapy 5

Important Caveats

Contraindications to Oxaliplatin

If oxaliplatin is contraindicated (severe neuropathy risk, significant comorbidities), consider:

• Single-agent fluoropyrimidine (5-FU/leucovorin or capecitabine) 1
• However, recognize this is less effective than combination therapy

Biological Behavior Considerations

GCA is more aggressive than typical appendiceal carcinoid but has mixed adenocarcinoma and neuroendocrine features 3, 5. Key points:

• Stage-specific survival for stage III GCA is approximately 22% at 5 years 6
• Lymph node involvement occurs in 8-28% of cases, primarily with T4 lesions 6, 5
• The tumor behaves more like adenocarcinoma than neuroendocrine tumor, justifying colorectal cancer-based chemotherapy protocols

Evidence Limitations

Critical caveat: The evidence for chemotherapy benefit in GCA is limited to case reports and small series. One older study showed minimal benefit from 5-FU/leucovorin alone 6, but more recent reports with oxaliplatin-based regimens show better outcomes 3, 4, 7. The addition of oxaliplatin appears crucial based on contemporary experience.

What NOT to Use

• Single-agent 5-FU/leucovorin alone: Historically shown to be minimally effective 6
• Neuroendocrine-directed chemotherapy: Despite neuroendocrine markers, GCA behaves predominantly as adenocarcinoma
• Observation alone: Given lymph node involvement (stage III disease), chemotherapy is indicated to reduce recurrence risk

Special Consideration: Bevacizumab

Adding bevacizumab to FOLFOX showed efficacy in one case report with peritoneal disease 7, but this should be reserved for:

• Metastatic/stage IV disease
• Not routinely recommended for adjuvant treatment of node-positive disease without distant metastases